Use of direct oral anticoagulants with regional anesthesia in orthopedic patients

Journal of Clinical Anesthesia

Volumn 32, Issue , 2016, Pages 224-235

  Cappelleri, Gianluca ^a   Fanelli, Andrea ^b  

^a ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Direct oral anticoagulant; Major orthopedic surgery; Neuraxial anesthesia; Perioperative management; Postoperative management

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANALGESIC AGENT; ANESTHETIC AGENT; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; ENOXAPARIN; HEPARIN; ITRACONAZOLE; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; MORPHINE; RITONAVIR; RIVAROXABAN; VERAPAMIL; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ANESTHESIST; ANTICOAGULANT THERAPY; BACKACHE; BLEEDING; CLINICAL PRACTICE; CREATININE CLEARANCE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; EPIDURAL ABSCESS; EPIDURAL ANESTHESIA; EPIDURAL HEMATOMA; GENERAL ANESTHESIA; HIP SURGERY; HUMAN; LABORATORY TEST; LUMBAR PLEXUS BLOCK; MAJOR SURGERY; NERVE BLOCK; NEUROLOGICAL COMPLICATION; ORTHOPEDIC SURGERY; PATIENT CARE; PERIOPERATIVE PERIOD; PERIPHERAL NERVE BLOCK; PERIPHERAL NERVE INJURY; PHASE 3 CLINICAL TRIAL (TOPIC); POSTDURAL PUNCTURE HEADACHE; POSTOPERATIVE CARE; POSTOPERATIVE PAIN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REGIONAL ANESTHESIA; REGIONAL NEURAXIAL ANESTHESIA; REVIEW; RISK FACTOR; SPINAL ANESTHESIA; SPINAL HEMATOMA; SURGICAL MORTALITY; SURGICAL RISK; TOTAL KNEE ARTHROPLASTY; URINARY EXCRETION; VENOUS THROMBOEMBOLISM; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, ORAL; ANESTHESIA, CONDUCTION; ANTICOAGULANTS; CLINICAL TRIALS, PHASE III AS TOPIC; FACTOR XA INHIBITORS; HUMANS; ORTHOPEDIC PROCEDURES; RIVAROXABAN;

EID: 84964391051     PISSN: 09528180     EISSN: 18734529     Source Type: Journal    
DOI: 10.1016/j.jclinane.2016.02.028     Document Type: Review

References (96)

1. S.B. Deitelzweig, B.H. Johnson, J. Lin, and K.L. Schulman Prevalence of clinical venous thromboembolism in the USA: current trends and future projections Am J Hematol 86 2011 217 220
2. D.A. MacDougall, A.L. Feliu, S.J. Boccuzzi, and J. Lin Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome Am J Health Syst Pharm 63 2006 S5 S15
3. A. Spyropoulos, and J. Lin Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations J Manag Care Pharm 13 2007 475 486
4. Y. Falck-Ytter, C.W. Francis, N.A. Johanson, C. Curley, O.E. Dhal, S. Schulman, and et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines Chest 141 2012 e278S e325S
5. J.D. Douketis, A.C. Spyropoulos, F.A. Spencer, M. Mayr, A.K. Jaffer, M.H. Eckman, and et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines Chest 141 2012 e326S e350S
6. Bristol-Myers Squibb, Pfizer. Eliquis® Summary of Product Characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002148/WC500107728.pdf [accessed 26/11/2015].
7. Bristol-Myers Squibb Company, Pfizer Inc. Eliquis® Prescribing Information. http://packageinserts.bms.com/pi/pi-eliquis.pdf [accessed 16/10/2015].
8. Boehringer Ingelheim International GmbH. Pradaxa® Summary of Product Characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000829/WC500041059.pdf [accessed 26/11/2015].
9. Boehringer Ingelheim Pharmaceuticals Inc. Pradaxa® Prescribing Information. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf [accessed 16/10/2015].
10. Bayer Pharma AG. Xarelto® Summary of Product Characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000944/WC500057108.pdf [accessed 25/11/2015].
11. Janssen Pharmaceuticals Inc. Xarelto® Prescribing Information. http://www.xareltohcp.com/sites/default/files/pdf/xarelto-0.pdf [accessed 16/10/2015].
12. C. Frost, J. Wang, S. Nepal, A. Schuster, Y.C. Barret, R. Mosqueda-Garcia, and et al. Apixaban, an oral, direct factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects Br J Clin Pharmacol 75 2013 476 487
13. D. Kubitza, M. Becka, B. Voith, M. Zuehlsdorf, and G. Wensing Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor Clin Pharmacol Ther 78 2005 412 421
14. D. Kubitza, M. Becka, G. Wensing, B. Voith, and M. Zuehlsdorf Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct factor Xa inhibitor - after multiple dosing in healthy male subjects Eur J Clin Pharmacol 61 2005 873 880
15. S. Blech, T. Ebner, E. Ludwig-Schwellinger, J. Stangier, and W. Roth The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans Drug Metab Dispos 36 2008 386 399
16. W. Upreti, J. Wang, Y.C. Barrett, W. Byon, R.A. Boyd, J. Pursley, and et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects Br J Clin Pharmacol 76 2013 908 916
17. D. Kubitza, M. Becka, M. Zuehlsdorf, and W. Mueck Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects J Clin Pharmacol 47 2007 218 226
18. D. Kubitza, M. Becka, A. Roth, and W. Mueck The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor J Clin Pharmacol 53 2013 249 255
19. K.H. Liesenfeld, T. Lehr, C. Dansirikul, P.A. Reilly, S.J. Connolly, M.D. Ezekowitz, and et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial J Thromb Haemost 9 2011 2168 2175
20. C.E. Frost, Y. Song, A. Shenker, J. Wang, Y.C. Barrett, A. Schuster, and et al. Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban Clin Pharmacokinet 54 2015 651 662
21. W. Mueck, J. Stampfuss, D. Kubitza, and M. Becka Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban Clin Pharmacokinet 53 2014 1 16
22. M.R. Lassen, G.E. Raskob, A. Gallus, G. Pineo, D. Chen, and R.J. Portman Apixaban or enoxaparin for thromboprophylaxis after knee replacement N Engl J Med 361 2009 594 604
23. M.R. Lassen, G.E. Raskob, A. Gallus, G. Pineo, D. Chen, P. Hornick, and et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial Lancet 375 2010 807 815
24. M.R. Lassen, A. Gallus, G.E. Raskob, G. Pineo, D. Chen, L.M. Ramirez, and et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement N Engl J Med 363 2010 2487 2498
25. A. Cohen, P. Drost, N. Marchant, S. Mitchell, M. Orme, D. Rublee, and et al. The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis Clin Appl Thromb Hemost 18 2012 611 627
26. S.E. Wolowacz, N.S. Roskell, J.M. Plumb, J.A. Caprini, and B.I. Eriksson Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis Thromb Haemost 101 2009 77 85
27. A.G. Turpie, M.R. Lassen, B.I. Eriksson, M. Gent, S.D. Berkowitz, F. Misselwitz, and et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies Thromb Haemost 105 2011 444 453
28. W. Ageno, A.S. Gallus, A. Wittkowsky, M. Crowther, E.M. Hylek, and G. Palareti Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines Chest 141 2012 e44S e88S
29. K.M. Rudd, and E.L. Phillips New oral anticoagulants in the treatment of pulmonary embolism: efficacy, bleeding risk, and monitoring Thrombosis 2013 2013 973710
30. D. Garcia, E. Libby, and M.A. Crowther The new oral anticoagulants Blood 115 2010 15 20
31. A. Rodgers, N. Walker, S. Schug, A. McKee, H. Kehlet, A. van Zundert, and et al. Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials Br Med J 321 2000 1493
32. D.J. Allen, S.H. Chae-Kim, and D.M. Trousdale Risks and complications of neuraxial anesthesia and the use of anticoagulation in the surgical patient Proc (Baylor Univ Med Cent) 15 2002 369 373
33. L. Green, and S.J. Machin Managing anticoagulated patients during neuraxial anaesthesia Br J Haematol 149 2010 195 208
34. A. Jabbari, E. Alijanpour, M. Mir, H.N. Bani, S.M. Rabiea, and M.A. Rupani Post spinal puncture headache, an old problem and new concepts: review of articles about predisposing factors Caspian J Intern Med 4 2013 595 602
35. K. Schwabe, and H.B. Hopf Persistent back pain after spinal anaesthesia in the non-obstetric setting: incidence and predisposing factors Br J Anaesth 86 2001 535 539
36. C.L. Jeng, T.M. Torrillo, and M.A. Rosenblatt Complications of peripheral nerve blocks Br J Anaesth 105 Suppl. 1 2010 i97 107
37. A. Agarwal, and K. Kishore Complications and controversies of regional anaesthesia: a review Indian J Anaesth 53 2009 543 553
38. Y. Auroy, D. Benhamou, L. Bargues, C. Ecoffey, B. Falissard, F.J. Mercier, and et al. Major complications of regional anesthesia in France: the SOS Regional Anesthesia Hotline Service Anesthesiology 97 2002 1274 1280
39. M.J. Barrington, S.A. Watts, S.R. Gledhill, R.D. Thomas, S.A. Said, G.L. Snyder, and et al. Preliminary results of the Australasian Regional Anaesthesia Collaboration: a prospective audit of more than 7000 peripheral nerve and plexus blocks for neurologic and other complications Reg Anesth Pain Med 34 2009 534 541
40. O. Stundner, Y.L. Chiu, X. Sun, M. Mazumdar, P. Fleischut, L. Poultsides, and et al. Comparative perioperative outcomes associated with neuraxial versus general anesthesia for simultaneous bilateral total knee arthroplasty Reg Anesth Pain Med 37 2012 638 644
41. T.T. Horlocker, D.J. Wedel, J.C. Rowlingson, F.K. Enneking, S.L. Kopp, H.T. Benzon, and et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines (third edition) Reg Anesth Pain Med 35 2010 64 101
42. M. Stafford-Smith Impaired haemostasis and regional anaesthesia Can J Anaesth 43 1996 R129 R141
43. T.T. Horlocker, and J.A. Heit Low molecular weight heparin: biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for regional anesthetic management Anesth Analg 85 1997 874 885
44. M.T. Pitkanen, U. Aromaa, D.A. Cozanitis, and J.G. Forster Serious complications associated with spinal and epidural anaesthesia in Finland from 2000 to 2009 Acta Anaesthesiol Scand 57 2013 553 564
45. M. Pumberger, S.G. Memtsoudis, O. Stundner, R. Herzog, F. Boettner, E. Gausden, and et al. An analysis of the safety of epidural and spinal neuraxial anesthesia in more than 100,000 consecutive major lower extremity joint replacements Reg Anesth Pain Med 38 2013 515 519
46. E. Oger, L. Bressollette, M. Nonent, K. Lacut, B. Guias, F. Couturaud, and et al. High prevalence of asymptomatic deep vein thrombosis on admission in a medical unit among elderly patients Thromb Haemost 88 2002 592 597
47. J.A. Heit, M.D. Silverstein, D.N. Mohr, T.M. Petterson, C.M. Lohse, W.M. O'Fallon, and et al. The epidemiology of venous thromboembolism in the community Thromb Haemost 86 2001 452 463
48. M.N. Levine, G. Raskob, S. Landefeld, and C. Kearon Hemorrhagic complications of anticoagulant treatment Chest 119 2001 108S 121S
49. C.S. Landefeld, and R.J. Beyth Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention Am J Med 95 1993 315 328
50. A.A. Mangoni, and S.H. Jackson Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications Br J Clin Pharmacol 57 2004 6 14
51. L. Lopez-Jimenez, M. Montero, J.A. Gonzalez-Fajardo, J.I. Arcelus, C. Suárez, J.L. Lobo, and et al. Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE) Haematologica 91 2006 1046 1051
52. K. Lacut, G. Le Gal, and D. Mottier Primary prevention of venous thromboembolism in elderly medical patients Clin Interv Aging 3 2008 399 411
53. E.P. Vandermeulen, H. Van Aken, and J. Vermylen Anticoagulants and spinal-epidural anesthesia Anesth Analg 79 1994 1165 1177
54. R.L. Ruff, and J.H. Dougherty Jr. Complications of lumbar puncture followed by anticoagulation Stroke 12 1981 879 881
55. T.T. Horlocker, and D.J. Wedel Neuraxial block and low-molecular-weight heparin: balancing perioperative analgesia and thromboprophylaxis Reg Anesth Pain Med 23 1998 164 177
56. G. Bettelli Anaesthesia for the elderly outpatient: preoperative assessment and evaluation, anaesthetic technique and postoperative pain management Curr Opin Anaesthesiol 23 2010 726 731
57. W. Gogarten, E. Vandermeulen, H. Van Aken, S. Kozek, J.V. Llau, and C.M. Samama Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology Eur J Anaesthesiol 27 2010 999 1015
58. V. Moen, N. Dahlgren, and L. Irestedt Severe neurological complications after central neuraxial blockades in Sweden 1990-1999 Anesthesiology 101 2004 950 959
59. V.L. Serebruany, S.R. Steinhubl, P.B. Berger, A.I. Malinin, D.L. Bhatt, and E.J. Topol Variability in platelet responsiveness to clopidogrel among 544 individuals J Am Coll Cardiol 45 2005 246 251
60. T.H. Baron, P.S. Kamath, and R.D. McBane Management of antithrombotic therapy in patients undergoing invasive procedures N Engl J Med 368 2013 2113 2124
61. H. Heidbuchel, P. Verhamme, M. Alings, M. Antz, W. Hacke, J. Oldgren, and et al. European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation Europace 15 2013 625 651
62. N. Rosencher, J.V. Llau, W. Mueck, A. Loewe, S.D. Berkowitz, and M. Homering Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin) Acta Anaesthesiol Scand 57 2013 565 572
63. N. Rosencher, H. Noack, M. Feuring, A. Clemens, R.J. Friedman, and B.I. Eriksson Type of anaesthesia and the safety and efficacy of thromboprophylaxis with enoxaparin or dabigatran etexilate in major orthopaedic surgery: pooled analysis of three randomized controlled trials Thromb J 10 2012 9
64. H. Breivik, U. Bang, J. Jalonen, G. Vigfússon, S. Alahuhta, and M. Lagerkranser Nordic guidelines for neuraxial blocks in disturbed haemostasis from the Scandinavian Society of Anaesthesiology and Intensive Care Medicine Acta Anaesthesiol Scand 54 2010 16 41
65. H.T. Benzon, M.J. Avram, D. Green, and R.O. Bonow New oral anticoagulants and regional anaesthesia Br J Anaesth 111 Suppl. 1 2013 i96 113
66. N. Rosencher, M.P. Bonnet, and D.I. Sessler Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategies Anaesthesia 62 2007 1154 1160
67. G. Connolly, and A.C. Spyropoulos Practical issues, limitations, and periprocedural management of the NOAC's J Thromb Thrombolysis 36 2013 212 222
68. A. Liew, and J. Douketis Perioperative management of patients who are receiving a novel oral anticoagulant Intern Emerg Med 8 2013 477 484
69. D. Imberti, A. Ambrosoli, C. Cimminiello, C. Compagnone, A. Fanelli, A. Tripodi, and et al. Periprocedural management of rivaroxaban-treated patients Expert Opin Pharmacother 16 2015 685 691
70. J. van Ryn, J. Stangier, S. Haertter, K.H. Liesenfeld, W. Wienen, M. Feuring, and et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb Haemost 103 2010 1116 1127
71. H. Heidbuchel, P. Verhamme, M. Alings, M. Antz, H.C. Diener, W. Hacke, and et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation Europace 17 2015 1467 1507
72. R.C. Becker, H. Yang, Y. Barrett, P. Mohan, J. Wang, L. Wallentin, and et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban - an oral, direct and selective factor Xa inhibitor J Thromb Thrombolysis 32 2011 183 187
73. T. Baglin, D. Keeling, and S. Kitchen Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology Br J Haematol 159 2012 427 429
74. E. Lindhoff-Last, M.M. Samama, T.L. Ortel, J.I. Weitz, and T.E. Spiro Assays for measuring rivaroxaban: their suitability and limitations Ther Drug Monit 32 2010 673 679
75. S.M. Bates, and J.I. Weitz Coagulation assays Circulation 112 2005 e53 e60
76. M.M. Samama, G. Contant, T.E. Spiro, E. Perzborn, L. Le Flem, C. Guinet, and et al. Laboratory assessment of rivaroxaban: a review Thromb J 11 2013 11
77. M.M. Samama, G. Contant, T.E. Spiro, E. Perzborn, C. Guinet, Y. Gourmelin, and et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls Thromb Haemost 107 2012 379 387
78. S. Haas, C. Bode, B. Norrving, and A.G.G. Turpie Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk Vasc Health Risk Manag 10 2014 101 114
79. A. Tripodi, V. Chantarangkul, C. Guinet, and M.M. Samama The international normalized ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study J Thromb Haemost 9 2011 226 228
80. W. Pfeilschifter, S. Luger, R. Brunkhorst, E. Lindhoff-Last, and C. Foerch The gap between trial data and clinical practice - an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation Cerebrovasc Dis 36 2013 115 119
81. J. Stangier, and M. Feuring Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran Blood Coagul Fibrinolysis 23 2012 138 143
82. A. Tripodi The laboratory and the new oral anticoagulants Clin Chem 59 2013 353 362
83. S. Kozek-Langenecker Management of massive operative blood loss Minerva Anestesiol 73 2007 401 415
84. P. Meybohm, K. Zacharowski, and C.F. Weber Point-of-care coagulation management in intensive care medicine Crit Care 17 2013 218
85. T.T. Horlocker Pain management in total joint arthroplasty: a historical review Orthopedics 33 2010 14 19
86. S.J. Fowler, J. Symons, S. Sabato, and P.S. Myles Epidural analgesia compared with peripheral nerve blockade after major knee surgery: a systematic review and meta-analysis of randomized trials Br J Anaesth 100 2008 154 164
87. The PROSPECT Group. Procedure specific postoperative pain management (PROSPECT) final recommendations; Overall Recommendations for Total Hip Arthroplasty, 11. http://www.postoppain.org/sections/?root-id=8861§ion=3# [accessed 03/11/2015].
88. P. Jaeger, D. Zaric, J.S. Fomsgaard, K.L. Hilsted, J. Bjerregaard, J. Gyrn, and et al. Adductor canal block versus femoral nerve block for analgesia after total knee arthroplasty: a randomized, double-blind study Reg Anesth Pain Med 38 2013 526 532
89. B.M. Ilfeld, K.B. Duke, and M.C. Donohue The association between lower extremity continuous peripheral nerve blocks and patient falls after knee and hip arthroplasty Anesth Analg 111 2010 1552 1554
90. C. Aveline, and F. Bonnet Delayed retroperitoneal haematoma after failed lumbar plexus block Br J Anaesth 93 2004 589 591
91. P. Bickler, J. Brandes, M. Lee, K. Bozic, B. Chesbro, and J. Claassen Bleeding complications from femoral and sciatic nerve catheters in patients receiving low molecular weight heparin Anesth Analg 103 2006 1036 1037
92. W. Gogarten The influence of new antithrombotic drugs on regional anesthesia Curr Opin Anaesthesiol 19 2006 545 550
93. M. Wiegel, U. Gottschaldt, R. Hennebach, T. Hirschberg, and A. Reske Complications and adverse effects associated with continuous peripheral nerve blocks in orthopedic patients Anesth Analg 104 2007 1578 1582 [table]
94. J.E. Chelly, and D. Schilling Thromboprophylaxis and peripheral nerve blocks in patients undergoing joint arthroplasty J Arthroplast 23 2008 350 354
95. C. Idestrup, M. Sawhney, C. Nix, and A. Kiss The incidence of hematoma formation in patients with continuous femoral catheters following total knee arthroplasty while receiving rivaroxaban as thromboprophylaxis: an observational study Reg Anesth Pain Med 39 2014 414 417
96. J.E. Chelly, B. Metais, D. Schilling, C. Luke, and D. Taormina Combination of superficial and deep blocks with rivaroxaban Pain Med 16 2015 2024 2030